NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have increased by 9.1% and is now trading at $8.72. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings data on Thursday, March, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.18. The company had revenue of $11 million for the quarter, compared to the consensus estimate of $11 million. Avadel Pharmaceuticals had a negative return on equity of 608.01% and a negative net margin of 56.11%. View Avadel Pharmaceuticals' earnings history.

Avadel Pharmaceuticals updated its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

5 brokerages have issued 1-year price targets for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

News headlines about AVDL stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutAvadel Pharmaceuticals.

Avadel Pharmaceuticals saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,953,100 shares, a drop of 43.9% from the February 27th total of 7,050,000 shares. Based on an average trading volume of 712,600 shares, the days-to-cover ratio is presently 5.5 days. Currently, 11.4% of the company's stock are sold short. View Avadel Pharmaceuticals' Current Options Chain.

Some companies that are related to Avadel Pharmaceuticals include Karyopharm Therapeutics (KPTI), Dicerna Pharmaceuticals (DRNA), CytoDyn (CYDY), Tricida (TCDA), Innoviva (INVA), TG Therapeutics (TGTX), ZEALAND PHARMA/S (ZEAL), Ligand Pharmaceuticals (LGND), Zogenix (ZGNX), Madrigal Pharmaceuticals (MDGL), I-Mab (ARQT), Heron Therapeutics (HRTX), NextCure (NXTC), Akebia Therapeutics (AKBA) and Esperion Therapeutics (ESPR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $8.72.

Avadel Pharmaceuticals has a market capitalization of $326.56 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe. View additional information about Avadel Pharmaceuticals.

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]